Преглед аутора: "Molden, Espen"
Приказ резултата 1-14 од 14
-
Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials
Milosavljević, Filip; Molden, Espen; Ingelman-Sundberg, Magnus; Jukić, Marin (Elsevier B.V., 2024) -
CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry
Molden, Espen; Jukić, Marin (Frontiers Media S.A., 2021) -
Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study
Jukić, Marin; Smith, Robert L.; Haslemo, Tore; Molden, Espen; Ingelman-Sundberg, Magnus (Elsevier Sci Ltd, Oxford, 2019) -
Impact of CYP2C19 and CYP2D6 polymorphism on antidepressants and antipsychotics exposure; a meta-analysis
Milosavljević, Filip; Bukvić, Nikola; Pavlović, Zorana; Miljević, Čedo; Pešić, Vesna; Molden, Espen; Ingelman-Sundberg, Magnus; Leucht, Stefan; Jukić, Marin (Elsevier, 2020) -
Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients
Jukić, Marin; Haslemo, Tore; Molden, Espen; Ingelman-Sundberg, Magnus (Amer Psychiatric Publishing, Inc, Washington, 2018) -
Impact of NFIB and CYP1A variants on clozapine serum concentration—A retrospective naturalistic cohort study on 526 patients with known smoking habits
Lenk, Hasan Çağın; Løvsletten Smith, Robert; O'Connell, Kevin; Jukić, Marin; Kringen, Marianne Kristiansen; Andreassen, Ole; Ingelman-Sundberg, Magnus; Molden, Espen (John Wiley and Sons Inc, 2022) -
Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population
Bråten, Line Skute; Ingelman-Sundberg, Magnus; Jukić, Marin; Molden, Espen; Kringen, Marianne Kristiansen (John Wiley and Sons Inc, 2022) -
Pharmacogenomics in treatment of depression and psychosis: an update
Jukić, Marin; Milosavljević, Filip; Molden, Espen; Ingelman-Sundberg, Magnus (Elsevier Ltd, 2022) -
Quantification of Antidepressant and Antipsychotic Exposure Increase Caused by CYP2C19 and CYP2D6 Intermediate and Poor Metabolizer Status
Milosavljević, Filip; Bukvić, Nikola; Pešić, Vesna; Pavlović, Zorana; Miljević, Čedo; Molden, Espen; Ingelman-Sundberg, Magnus; Jukić, Marin (Springer Nature, 2019) -
Quantification of antidepressant and antipsychotic exposure increase caused by CYP2C19 and CYP2D6 intermediate and poor metabolizer status by meta-analysis
Milosavljević, Filip; Bukvić, Nikola; Pešić, Vesna; Molden, Espen; Ingelman-Sundberg, Magnus; Jukić, Marin (Elsevier, 2019) -
Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders
Smith, Robert; Tveito, Marit; Kyllesø, Lennart; Jukić, Marin; Ingelman-Sundberg, Magnus; Andreassen, Ole; Molden, Espen (Elsevier B.V., 2021) -
Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients
Haslemo, Tore; Eliasson, Erik; Jukić, Marin; Ingelman-Sundberg, Magnus; Molden, Espen (Wiley, Hoboken, 2019) -
The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients
Lenk, Hasan Çağın; Klöditz, Katharina; Johansson, Inger; Løvsletten Smith, Robert; Jukić, Marin; Molden, Espen; Ingelman-Sundberg, Magnus (John Wiley and Sons Inc, 2022) -
What is the Current Clinical Impact of the CYP2CTG Haplotype?
Ingelman-Sundberg, Magnus; Jukić, Marin; Bråten, Line Skute; Kringen, Marianne Kristiansen; Molden, Espen (John Wiley and Sons Inc, 2024)